Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Update on Bevacizumab Product for AMD
Outlook Therapeutics shared that it received a complete response letter (CRL) from the FDA for ONS-5010, a bevacizumab product intended for the treatment of neovascular age-related macular degeneration (wet-AMD).
Bevacizumab products, including Amgen’s reference bevacizumab (Avastin), are often used off-label to treat wet-AMD. There are currently 4 bevacizumab biosimilars approved in the United States. However, because the reference product does not have an indication for wet-AMD, bevacizumab biosimilar manufacturers are not allowed to obtain this indication. Therefore, if it is eventually approved, it must be approved as a new drug and would not be classified as a biosimilar.
In the CRL, the FDA requested more data from “an additional adequate and well-controlled study to support the ONS-5010 BLA [biologics license application].” The analysis must evaluate ONS-5010 vs reference ranibizumab (Lucentis) over a 3-month period. The patients must be naïve to vascular endothelial growth factor receptor inhibitors (bevacizumab and ranibizumab).
Outlook Therapeutics said that it is working with the FDA’s Division of Ophthalmology to design an appropriate study to satisfy FDA’s requirement. The company projected that will resubmit its BLA for ONS-5010 by the end of 2024.
Samsung Bioepis Settles With J&J
Samsung Bioepis announced that it signed a settlement and license agreement with J&J, clearing the way for Samsung Biopeis’ SB17, a biosimilar referencing J&J’s Stelara (ustekinumab), to enter the US market pending FDA approval.
Under the terms of the agreement, Samsung Bioepis will be able to launch SB17 no earlier than February 22, 2025. The date is similar to those agreed upon during other J&J settlements with ustekinumab biosimilar manufacturers, including Amgen and Teva/Alvotech.
“We welcome this agreement which clears the way for SB17 in the US, which has a potential to broaden access to treatment for patients suffering inflammatory conditions,” said Kris Soyoung Lee, vice president and commercial team leader at Samsung Bioepis.
Ustekinumab products are human immunoglobulin G1k monoclonal antibodies that prevent abnormal regulation of IL-12 and IL-23, which are associated with several immunology diseases. Stelara is approved to treat plaque psoriasis, Crohn disease, ulcerative colitis, and psoriatic arthritis. If the FDA approves SB17, the product will be marketed by Sandoz as part of a September 2023 commercialization agreement.
Another Trastuzumab Biosimilar Receives EU Approval
The European Commission granted Sandoz and EirGenix marketing authorization for their trastuzumab biosimilar (Herwenda), making it the eighth biosimilar referencing Herceptin to be approved in the region.
Trastuzumab products are monoclonal antibodies that are used to treat patients with HER2-positive breast and gastric cancers. The reference product generated about $1.4 billion in year-to-date sales in September 2023, according to financial records from Roche, the maker of Herceptin.
The European Medicines Agency’s Committee for Medicinal Products for Human Use gave a positive recommendation for approval in September 2023. The approval and recommendation were based on a data package containing data from phase 1 and phase 3 trials. The phase 3 study including 807 patients demonstrated that the biosimilar was comparable in safety and efficacy to the reference product.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Paving the Way for Equitable Biosimilar Access in Australian Dermatology Clinics
May 13th 2025Australia’s growing reliance on high-cost biologics for inflammatory skin diseases has placed significant pressure on its health system—but a new report suggests biosimilars could offer financial relief, provided uptake barriers are addressed through policy reform and education.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.